



# Product Sheet

## CellVantage™-AAV

Version: 03

Research Grade Material, *not for human use*

Product #: 107010  
Batch#: V91PiR01  
Storage: 20 ± 5°C, protect from light  
Stability: Use within 1 year of receipt

### Product Description

CellVantage™-AAV is a powerful media additive designed to significantly improve Adeno-Associated Virus (AAV) production efficiency, enabling higher yields without altering your existing workflow. CellVantage™-AAV helps you generate high-titer AAV preparations more efficiently to accelerate research and development.

Analytical Method	Acceptance Criteria	Result
Visual Appearance	White powder	White powder
ID by LC-MS	Conforms to the reference standard	Conforms to the reference standard
Purity by LC-MS (% area)	≥ 94.0	96.2
Solubility	Dissolved at 10 mM in DMSO	Pass
Biological Activity of AAV Production assessed by Genomic Titer Assay*	≥ 1.5-fold change	Pass

### \* Functional Assay

CellVantage™-AAV is tested in combination with PEI-based transfection reagent for enhanced AAV production in HEK293-based suspension cells using a reporter-encoded transfer vector. Viral titer is quantified by viral genome (vg) copies using qPCR and the averaged result is expressed as a fold increase over a control baseline titer.

4-Mar-2026

Denise van Rossum, VP Product Development

4-Mar-2026

Terrence Cochrane (Mar 4, 2026 11:07:39 EST)

Terrence Cochrane, Acting Head of Quality









# PS-VSE-007-V91PIR01\_v03\_20260304

Final Audit Report

2026-03-04

Created:	2026-03-04
By:	Erica Marchus (e.m@brevisrefero.com)
Status:	Approved
Transaction ID:	CBJCHBCAABAAg9cwwGVdOdsnV0oWku53Dz-mdW4o28Zm

## "PS-VSE-007-V91PIR01\_v03\_20260304" History

-  Document created by Erica Marchus (e.m@brevisrefero.com)  
2026-03-04 - 3:40:36 PM GMT
-  Document emailed to Denise van Rossum (dvanrossum@viricabiotech.com) for approval  
2026-03-04 - 3:40:41 PM GMT
-  Email viewed by Denise van Rossum (dvanrossum@viricabiotech.com)  
2026-03-04 - 4:05:57 PM GMT
-  Document approved by Denise van Rossum (dvanrossum@viricabiotech.com)  
Approval Date: 2026-03-04 - 4:06:47 PM GMT - Time Source: server
-  Document emailed to Terrence Cochrane (t.c@brevisrefero.com) for approval  
2026-03-04 - 4:06:49 PM GMT
-  Email viewed by Terrence Cochrane (t.c@brevisrefero.com)  
2026-03-04 - 4:07:09 PM GMT
-  Document approved by Terrence Cochrane (t.c@brevisrefero.com)  
Approval Date: 2026-03-04 - 4:07:39 PM GMT - Time Source: server
-  Agreement completed.  
2026-03-04 - 4:07:39 PM GMT